Dr. Finkle is boarded in Internal Medicine, Cardiology and Clinical Cardiac Electrophysiology. He works in the Clinical Safety Department at GSK and is Chair of the Global QT and Cardiology Safety Panels. Dr. Finkle also sits on Executive Steering Committee of the Cardiac Safety Research Consortia

Greg Powell is the Senior Director of Safety and Clinical Innovation at GlaxoSmithKline. He completed his PharmD at the University of Florida, his MBA at East Carolina University, and his BS in Pharmacy at the University of North Carolina. He has over twenty years of experience practicing pharmacovigilance across the entire product life cycle. Additionally, he has focused on advancing the science of pharmacovigilance working with various data/methods that range from traditional data sources such as spontaneous, clinical trial, and observational to emerging data sources such as social media, crowdsourcing, and artificial intelligence. He has extensively published his work in various journals and presented at various conferences.

She is the Deputy Dir. of Safety (Div. of Cardiovascular/Renal Products). Responsibilities include evaluation of NDAs under review for relevant post-marketing activities such as Risk Evaluation and Mitigation Plans, enhanced pharmacovigilance, and required post-marketing studies.